The DOI matches its Crossref record; 314 of the 318 references it cites were found in a registry or an index.
Self-assembled mRNA vaccines
Open accessAbstract
mRNA vaccines have evolved from being a mere curiosity to emerging as COVID-19 vaccine front-runners. Recent advancements in the field of RNA technology, vaccinology, and nanotechnology have generated interest in delivering safe and effective mRNA therapeutics. In this review, we discuss design and self-assembly of mRNA vaccines. Self-assembly, a spontaneous organization of individual molecules, allows for design of nanoparticles with customizable properties. We highlight the materials commonly utilized to deliver mRNA, their physicochemical characteristics, and other relevant considerations, such as mRNA optimization, routes of administration, cellular fate, and immune activation, that are important for successful mRNA vaccination. We also examine the COVID-19 mRNA vaccines currently in clinical trials. mRNA vaccines are ready for the clinic, showing tremendous promise in the COVID-19 vaccine race, and have pushed the boundaries of gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a result, one copy of saRNA produces multiple copies of RNA transcripts by the above-described mechanism to initiate self-amplification of antigen genes in the cell.35,195,196”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [35]
In the citing paper
“Hence, the delivery vector employed in saRNA vaccines must allow for higher loading capacity and encapsulation efficiency.35”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [35]
In the citing paper
“Tfh cells recognize antigens on the APC surface and help to activate B cells, which in turn produce high-affinity virus-neutralizing antibodies.6,55, 56, 57”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [56]
In the citing paper
“Tfh cells further help activate CD8+ cytotoxic T cells that may specifically recognize and eliminate virus-infected cells (Figure 1).6,55, 56, 57”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [56]
In the citing paper
“These lipids can improve nanoparticle properties, such as particle stability, delivery efficacy, tolerability and biodistribution7,14,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“In addition to cationic or ionizable lipids, lipid nanoparticle–mRNA formulations typically contain other lipid components, such as phospholipids (for example, phosphatidylcholine and phosphatidylethanolamine), cholesterol or polyethylene glycol (PEG)-functionalized lipids (PEG-lipids)7,14,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“This structural feature protects mRNA molecules from nuclease degradation and increases nanoparticle stability in physiological fluids17,46.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“Lipid nanoparticle–mRNA formulations manufactured by rapid mixing exhibit a stable nanostructure17,130,131, in which mRNA molecules can be encapsulated in the interior core through electrostatic interactions with the lipids17,131.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“Incorporating PEG-lipids further decreases recognition by the MPS and clearance by renal filtration17,127.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“This technique allows reproducible and scalable production of lipid nanoparticle–mRNA formulations that show high encapsulation efficiency and homogeneous size distribution17,131.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“mRNA-1273 is stored at −15 °C to −20 °C and is directly injected after thawing17, whereas BNT162b2 is stored at −60 °C to −80 °C and requires thawing and dilution by saline before injection17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“mRNA-1273 is stored at −15 °C to −20 °C and is directly injected after thawing17, whereas BNT162b2 is stored at −60 °C to −80 °C and requires thawing and dilution by saline before injection17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“Of note, the authorized COVID-19 mRNA vaccines are both stored in freezing conditions in the presence of sucrose17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“The IVT mRNA molecules used in the mRNA-1273 and BNT162b2 COVID-19 vaccines were prepared by replacing uridine with m1ψ17,19,21, and their sequences were optimized to encode a stabilized pre-fusion spike protein with two pivotal proline substitutions17,19,21.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“For example, the clinical-grade COVID-19 vaccine, mRNA-1273, was produced within a month after the SARS-CoV-2 genome sequence was available15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“About 2, 5 and 6 months from sequence availability, clinical trial phases I, II and III were initiated, respectively15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“Finally, mRNA-1273 obtained Emergency Use Authorization from the FDA and conditional marketing authorization from the EMA within a year15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“These features make lipid nanoparticle–mRNA formulations a flexible and on-demand vaccine platform to rapidly respond to emerging infectious pathogens4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“First, mRNA is a non-infective and non-integrating agent with the ability to encode a broad range of antigens4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“Since then, lipid nanoparticle–mRNA formulations have emerged as a potent alternative to conventional vaccine platforms, owing to their unique features4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
In the citing paper
“Finally, GMP-grade lipid nanoparticle-mRNA vaccines can be manufactured for specific antigens in a short period of time, compared with other vaccine platforms, such as recombinant proteins and inactivated vaccines2,4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Whitesides, G. M., & Grzybowski, B. A. (2002) · Science · doi:10.1126/science.1070821 · Cited by 7,550
Biological properties of extracellular vesicles and their physiological functions
Yáñez‐Mó, M., Siljander, P. R. ‐., Andreu, Z., Bedina Zavec, A., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27066 · Cited by 5,926
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., RINGOLD, G. M., & Danielsen, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7413 · Cited by 4,954
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Flagged first, then by citations
4 of the 318 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Walsh, 2020, Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates, N. Engl. J. Med., 10.1056/NEJMoa2027906 · DOI · Paper page
- Tanaka, 2020, Self-degradable lipid-like materials based on “hydrolysis accelerated by the intra-particle enrichment of reactant (HyPER)” for messenger RNA delivery, Adv. Funct. Mater., 34, 1910575, 10.1002/adfm.201910575 · DOI · Paper page
- Mulligan, 2020, Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults, Nature, 586, 589, 10.1038/s41586-020-2639-4 · DOI · Paper page
Cited by
Sorted by citations
Items 101–200 of 514
Shi, R., Liu, X., Wang, Y., Pan, M., Wang, S., Shi, L., & Ni, B. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2342592 · Cited by 48
Strategy of developing nucleic acid-based universal monkeypox vaccine candidates
Papukashvili, D., Rcheulishvili, N., Liu, C., Wang, X., He, Y., & Wang, P. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1050309 · Cited by 45
Engineered mRNA Delivery Systems for Biomedical Applications
Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 46
Zhang, W., Pfeifle, A., Lansdell, C., Frahm, G. E., Cecillon, J., Tamming, L. A., Gravel, C., Gao, J., Raman, S. N. T., Wang, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11101580 · Cited by 45
Lipid Nanoparticle-Based Delivery SystemA Competing Place for mRNA Vaccines
Zhang, X., Li, Y., & Zhou, Z. (2024) · ACS Omega · doi:10.1021/acsomega.3c08353 · Cited by 43
Transfection Potency of Lipid Nanoparticles Containing mRNA Depends on Relative Loading Levels
Liao, S., Wang, S., Wadhwa, A., Birkenshaw, A., Fox, K., Cheng, M. H. Y., Casmil, I. C., Magaña, A. A., Bathula, N. V., Ho, C.-H., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c20077 · Cited by 47
Kumar, G., & Ardekani, A. M. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c01716 · Cited by 48
Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment
Karim, M. E., Haque, S. T., Al-Busaidi, H., Bakhtiar, A., Tha, K. K., Holl, M. M. B., & Chowdhury, E. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01418-x · Cited by 45
Application of microfluidic technologies on COVID-19 diagnosis and drug discovery
Lin, Z., Zou, Z., Pu, Z., Wu, M., & Zhang, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.014 · Cited by 44
Ramezanpour, M., & Tieleman, D. P. (2022) · Langmuir · doi:10.1021/acs.langmuir.2c00430 · Cited by 44
Kim, J., Jozić, A., Mukherjee, A., Nelson, D., Chiem, K., Khan, M. S. R., Torrelles, J. B., Martínez‐Sobrido, L., & Sahay, G. (2022) · Advanced Science · doi:10.1002/advs.202202556 · Cited by 49
Self-citationThe Development of mRNA Vaccines for Infectious Diseases: Recent Updates
Nitika, Wei, J., & Hui, A. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s341694 · Cited by 42
Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies
Du, L., Yang, Y., Zhang, X., & Li, F. (2021) · Nanoscale · doi:10.1039/d1nr03831a · Cited by 43
A robust post-insertion method for the preparation of targeted siRNA LNPs
Swart, L. E., Koekman, A. C., Seinen, C. W., Issa, H., Rasouli, M., Schiffelers, R. M., & Heidenreich, O. T. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121741 · Cited by 40
Yang, J., Luly, K. M., & Green, J. J. (2023) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1853 · Cited by 40
Advances in vaccine delivery systems against viral infectious diseases
Kim, D., Wu, Y., Kim, Y. B., & Oh, Y. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00945-2 · Cited by 41
Advanced Materials for SARS‐CoV‐2 Vaccines
Mabrouk, M. T., Huang, W., Martínez‐Sobrido, L., & Lovell, J. F. (2021) · Advanced Materials · doi:10.1002/adma.202107781 · Cited by 38
Glycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine
Wu, C., Cheng, C.-W., Kung, C., Liao, K., Jan, J., Ma, C., & Wong, C. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2119995119 · Cited by 39
Are inhaled mRNA vaccines safe and effective? A review of preclinical studies
Jansen, E. M., Frijlink, H. W., Hinrichs, W. L. J., & Ruigrok, M. J. R. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2131767 · Cited by 37
Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy
Wang, H., Wang, Z.-G., & Liu, S. (2022) · Molecules · doi:10.3390/molecules27175607 · Cited by 41
Ebenezer, O., Comoglio, P., Wong, G. K.-S., & Tuszynski, J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044019 · Cited by 39
In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future
Perenkov, A. D., Sergeeva, A. D., Vedunova, M. V., & Krysko, D. V. (2023) · Vaccines · doi:10.3390/vaccines11101600 · Cited by 40
Alshehry, Y., Liu, X., Zhang, Y., & Zhu, G. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113617 · Cited by 39
Nanotechnology for immuno-oncology
Grippin, A., Lee, D., Parkes, E. E., Jiang, W., & Kim, B. Y. S. (2025) · Nature Cancer · doi:10.1038/s43018-025-01025-x · Cited by 48
mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy
Haghmorad, D., Eslami, M., Orooji, N., Halabitska, I., Kamyshna, I. I., Kamyshnyi, O., & Oksenych, V. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1547025 · Cited by 42
Medjmedj, A., Loth, A. N., Clémençon, R., Hamáček, J., Pichon, C., & Perche, F. (2022) · Nanomaterials · doi:10.3390/nano12142446 · Cited by 39
Micro and nanotechnologies: The little formulations that could
Stiepel, R. T., Duggan, E., Batty, C. J., & Ainslie, K. M. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10421 · Cited by 38
Synthetic circRNA therapeutics: innovations, strategies, and future horizons
Cai, J., Qiu, Z., Cho, W. C. S., Liu, Z., Chen, S., Li, H., Chen, K., Li, Y., Zuo, C., & Qiu, M. (2024) · MedComm · doi:10.1002/mco2.720 · Cited by 42
Hourdel, L., Lebaz, N., Peral, F., Ripoll, M., Briançon, S., Bensaid, F., Luthra, S., & Cogné, C. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125297 · Cited by 37
Machine learning techniques for lipid nanoparticle formulation
Li, H., Zhao, Y., & Xu, C. (2025) · Nano Convergence · doi:10.1186/s40580-025-00502-4 · Cited by 40
Alharbi, M. S., Moursi, S. A., Alshammari, A. O., Aboras, R., Rakha, E., Hossain, A., Alshubrumi, S., Alnazha, K., Khaja, A. S. S., & Saleem, M. (2025) · Virulence · doi:10.1080/21505594.2025.2580160 · Cited by 44
AboulFotouh, K., Southard, B., Dao, H. M., Xu, H., Moon, C., Williams, R. O., & Cui, Z. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123688 · Cited by 34
Moayedpour, S., Broadbent, J., Riahi, S., Bailey, M., Thu, H. V., Dobchev, D. A., Balsubramani, A., dos Santos, R. N., Kogler-Anele, L., Corrochano-Navarro, A., et al. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae342 · Cited by 38
Kamanzi, A., Zhang, Y., Gu, Y., Liu, F., Berti, R., Wang, B. L., Saadati, F., Ciufolini, M. A., Kulkarni, J. A., Cullis, P. R., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c12981 · Cited by 35
Zwitterionic materials for nucleic acid delivery and therapeutic applications
He, S., & Liu, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.017 · Cited by 33
Adenoviral Vector COVID-19 Vaccines: Process and Cost Analysis
Ferreira, R. G., Gordon, N. F., Stock, R., & Petrides, D. P. (2021) · Processes · doi:10.3390/pr9081430 · Cited by 36
Opportunities and Challenges for mRNA Delivery Nanoplatforms
Zhang, Y., Hu, Y., Tian, H., & Chen, X. (2022) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c03898 · Cited by 33
Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges
Hassan, J., Haigh, C., Ahmed, T., Uddin, M. J., & Das, D. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051066 · Cited by 36
Chen, M., Cen, J., Shi, Q., Shao, B., Tan, J., Ye, X., He, Z., Liu, Y., Zhang, G., Hu, J., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202500878 · Cited by 32
Nanomaterials for targeted therapy of kidney diseases: Strategies and advances
Wang, Z., & Zhang, C. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101534 · Cited by 33
Inhalable mRNA vaccines for respiratory diseases: a roadmap
Roh, E. H., Fromen, C. A., & Sullivan, M. O. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.10.017 · Cited by 32
mRNA COVID-19 Vaccines—Facts and Hypotheses on Fragmentation and Encapsulation
Jacques Demongeot, A., & Fougère, C. (2022) · Vaccines · doi:10.3390/vaccines11010040 · Cited by 36
Harnessing synthetic biology for advancing RNA therapeutics and vaccine design
Pfeifer, B. A., Beitelshees, M., Hill, A. B., Bassett, J., & Jones, C. H. (2023) · npj Systems Biology and Applications · doi:10.1038/s41540-023-00323-3 · Cited by 33
Călina, D. C., Hernández, A. F., Härtung, T., Egorov, A. M., Izotov, B. N., Νikolouzakis, Τ. Κ., Tsatsakis, A. M., Vlachoyiannopoulos, P. G., & Docea, A. O. (2021) · Life · doi:10.3390/life11090907 · Cited by 31
Walde, P., & Ichikawa, S. (2021) · Applied Sciences · doi:10.3390/app112110345 · Cited by 31
Precision-engineering of subunit vaccine particles for prevention of infectious diseases
Chen, S., Pounraj, S., Sivakumaran, N., Kakkanat, A., Sam, G., Kabir, M. T., & Rehm, B. H. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1131057 · Cited by 32
Path towards mRNA delivery for cancer immunotherapy from bench to bedside
Chen, W., Zhu, Y., He, J., & Sun, X. (2023) · Theranostics · doi:10.7150/thno.89247 · Cited by 33
Zwitterionic Polymer-Decorated Lipid Nanoparticles for mRNA Delivery in Mammalian Cells
Khunsuk, P.-O., Pongma, C., Palaga, T., & Hoven, V. P. (2023) · Biomacromolecules · doi:10.1021/acs.biomac.3c00649 · Cited by 30
Freeze-Drying of mRNA-LNPs Vaccines: A Review
Khan, M. F. H., Baudin, F., Perumal, A. S., & Kamen, A. (2025) · Vaccines · doi:10.3390/vaccines13080853 · Cited by 37
Bouazzaoui, A., & Abdellatif, A. A. H. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100500 · Cited by 31
Zhao, Y., Wang, Z. M., Song, D., Chen, M., & Xu, Q. (2024) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2024.102499 · Cited by 30
Recent Advances in Delivery Systems for Genetic and Other Novel Vaccines
Huang, S., Zhu, Y., Zhang, L., & Zhang, Z. (2021) · Advanced Materials · doi:10.1002/adma.202107946 · Cited by 28
Feng, S., Rcheulishvili, N., Jiang, X., Zhu, P., Pan, X., Wei, M., Wang, P. G., Ji, Y., & Papukashvili, D. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.87741 · Cited by 27
Ahmed, S., & Herschhorn, A. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00041-24 · Cited by 29
Subcellular delivery of lipid nanoparticles to endoplasmic reticulum and mitochondria
Shi, Y., Luo, Z., & You, J. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1803 · Cited by 30
Hou, Y., Kong, F., Tang, Z., Zhang, R., Li, D., Ge, J., Yu, Z., Wahab, A., Zhang, Y., Iqbal, M. Z., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.050 · Cited by 26
Hajjo, R., Sabbah, D. A., & Tropsha, A. (2022) · Pathogens · doi:10.3390/pathogens11070743 · Cited by 28
Theranostic Lipid Nanoparticles for Renal Cell Carcinoma
Mao, X., Wang, G., Wang, Z., Duan, C., Wu, X., & Xu, H. (2023) · Advanced Materials · doi:10.1002/adma.202306246 · Cited by 29
Enhancing Cancer Immunotherapeutic Efficacy with Sonotheranostic Strategies
Zafar, A., Hasan, M., Tariq, T., & Dai, Z. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00437 · Cited by 25
mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
Jin, Y., Hou, C., Li, Y., Zheng, K., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.821538 · Cited by 24
Korzun, T., Moses, A. S., Kim, J., Patel, S., Schumann, C., Levasseur, P. R., Diba, P., Olson, B. G., Rebola, K. G. D. O., Norgard, M. A., et al. (2022) · Small · doi:10.1002/smll.202204436 · Cited by 25
Self-citationEmergence of mRNA vaccines in the management of cancer
Razif, M. I. M., Nizar, N., Abidin, N. H. Z., Ali, S. N. M., Zarimi, W. N. N. W., Khotib, J., Darnis, D. S., Jailani, M. T. M., & Taher, M. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2232450 · Cited by 23
Lipids: An Atomic Toolkit for the Endless Frontier
Shi, A., & Claridge, S. A. (2021) · ACS Nano · doi:10.1021/acsnano.1c07428 · Cited by 23
Designer phospholipids – structural retrieval, chemo-/bio- synthesis and isotopic labeling
Bogojevic, O., Nygaard, J. V., Wiking, L., Arevång, C., & Guo, Z. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2022.108025 · Cited by 23
Deng, J., Fukushima, Y., Nozaki, K., Nakanishi, H., Yada, E., Terai, Y., Fueki, K., & Itaka, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091785 · Cited by 27
Ji, A., Xu, M., Pan, Y., Diao, L., Ma, L., Li, Q., Cheng, J., & Liu, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03445-1 · Cited by 24
De, A., & Ko, Y. T. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2153832 · Cited by 24
Zhang, Y., Li, D., Shen, Y., Li, S., Lu, S., & Zheng, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161507 · Cited by 23
Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses
Kutikuppala, L. V. S., Kourampi, I., Kanagala, R. S. D., Bhattacharjee, P., & Boppana, S. H. (2024) · Medical Sciences · doi:10.3390/medsci12020028 · Cited by 24
Cao, L., Yu, Y.-F., Li, Z., Zhong, N., Wang, G.-R., Xiao, Y., Liu, B., Wu, Q., Feng, C., & Bu, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02590-6 · Cited by 28
Understanding In Vivo Fate of Nucleic Acid and Gene Medicines for the Rational Design of Drugs
Fumoto, S., Yamamoto, T., Okami, K., Maemura, Y., Terada, C., Yamayoshi, A., & Nishida, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020159 · Cited by 23
Coarse-Grained Simulation of mRNA-Loaded Lipid Nanoparticle Self-Assembly
Grzetic, D. J., Hamilton, N. B., & Shelley, J. C. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00216 · Cited by 22
Ferreira, H. A. S., Scalzo, S., de Faria, K. K. S., da Silva, G. H. C., Alves, M. T. R., Lobo, A. O., & Guimarães, P. P. G. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124696 · Cited by 22
Interaction design in mRNA delivery systems
Yu, M., Lin, L., Zhou, D., & Liu, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.038 · Cited by 25
Microfluidics for Nanomedicine Delivery
Chen, K., Yang, H., & Cai, R. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c02052 · Cited by 25
Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives
Shang, D., Zhou, Z., Shi, R., Wang, Z., Zhang, P., Fu, P., Li, H., Cheng, G., Qin, H., Xie, Z., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02476-7 · Cited by 26
mRNA delivery technologies: Toward clinical translation
Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.010 · Cited by 23
Anchoring super-enhancer-driven oncogenic lncRNAs for anti-tumor therapy in hepatocellular carcinoma
Yuan, X., Zhou, N., Wang, J., Yang, X., Wang, S., Zhang, C., Li, G., & Peng, L. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.013 · Cited by 24
The mRNA vaccine, a swift warhead against a moving infectious disease target
Mir, S., & Mir, M. A. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2320327 · Cited by 28
Zhao, H., Ma, S., Qi, Y., Gao, Y., Zhang, Y., Li, M., Chen, J., Song, W., & Chen, X. (2024) · Materials Horizons · doi:10.1039/d3mh02066e · Cited by 21
Advances in the study of LNPs for mRNA delivery and clinical applications
Wang, B., Shen, B., Xiang, W., & Shen, H. (2024) · Virus Genes · doi:10.1007/s11262-024-02102-6 · Cited by 22
Wu, K., Wang, Z., Yang, X., Chen, Y., Mastrogiovanni, F., Zhang, J., & Liu, L. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf307 · Cited by 23
Improved transfer efficiency of supercharged 36 + GFP protein mediate nucleic acid delivery
Wang, L., Geng, J., Chen, L., Guo, X., Wang, T., Fang, Y., Belingon, B., Wu, J., Li, M., Zhan, Y., et al. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2030430 · Cited by 21
Multifunctional Lipid Nanoparticles for Protein Kinase N3 shRNA Delivery and Prostate Cancer Therapy
Wang, J., Zhang, Y., Liu, C., Zha, W., Dong, S., Xing, H., & Li, X. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00244 · Cited by 21
Material Design for Next-Generation mRNA Vaccines Using Lipid Nanoparticles
Higuchi, A., Sung, T., Wang, T., Ling, Q., Kumar, S. S., Hsu, S.-T., & Umezawa, A. (2022) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2022.2106490 · Cited by 21
The clinical progress and challenges of mRNA vaccines
Yu, M., Wang, N., Zhu, J., & Lin, Y. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1894 · Cited by 23
Nanoadjuvants: Promising Bioinspired and Biomimetic Approaches in Vaccine Innovation
Desai, D. N., Mahal, A., Varshney, R., Obaidullah, A. J., Gupta, B., Mohanty, P., Pattnaik, P., Mohapatra, N. C., Mishra, S., Kandi, V., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c02030 · Cited by 20
Du, X., Yada, E., Terai, Y., Takahashi, T., Nakanishi, H., Tanaka, H., Akita, H., & Itaka, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092291 · Cited by 21
Zimmermann, C. M., Deßloch, L., Jürgens, D. C., Luciani, P., & Merkel, O. M. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.11.007 · Cited by 21
Harnessing RNA Technology to Advance Therapeutic Vaccine Antigens against Chagas Disease
Mancino, C., Pollet, J. B. K., Zinger, A., Jones, K. M., Villar, M. J., Leão, A. C., Adhikari, R., Versteeg, L., Kundu, R. T., Strych, U., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c18830 · Cited by 23
Liu, J., Xiao, B., Yang, Y., Jiang, Y., Wang, R., Qi, W. D., Pan, Y., Chen, Y., Wang, H., Fan, J., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c06160 · Cited by 20
Hassanel, D. N. B. P., Ju, Y., Takanashi, A., Algarni, A., Lee, C. L., Kent, S. J., Pouton, C. W., & Pilkington, E. H. (2025) · Nanoscale Horizons · doi:10.1039/d5nh00230c · Cited by 20
Advances of nanomaterials‐based strategies for fighting against COVID‐19
Zeng, C., Hou, X., Bohmer, M., & Dong, Y. (2021) · Open Research (University of Surrey) · doi:10.1002/viw.20200180 · Cited by 19
Li, Z., Shen, L., Ma, A. L., Talkington, A., Li, Z., Nyborg, A. C., Bowers, M. S., LaMoreaux, B. D., Livingston, E. W., Frank, J. E., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.08.052 · Cited by 20
Lipid nanoparticle technology-mediated therapeutic gene manipulation in the eyes
Wang, T., Yu, T., Liu, Q., Sung, T., & Higuchi, A. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102236 · Cited by 20
Vosoughi, P., Naghib, S. M., Kangarshahi, B. M., & Mozafari, M. R. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.139532 · Cited by 23
Isolating Nanoparticles from Complex Biological Media by Immunoprecipitation
Hacene, Y. C., Loiseau, A., Maio, V. D. P., Grenier, P., Boisselier, É., & Bertrand, N. (2021) · Nano Letters · doi:10.1021/acs.nanolett.0c05056 · Cited by 21
Iterative Screening of Vitamin E-Based Functional Lipid Nanoparticles for mRNA Delivery
Cui, K., Zhang, F., Shi, T., Zhao, S., Zhou, Y., Liu, X., Hu, Y. Y., Hu, Z., Kong, L., & Zhang, Z. (2025) · ACS Nano · doi:10.1021/acsnano.5c01378 · Cited by 20
Cao, M., Li, Y., Song, X., Lu, Z., Zhai, H., Qiu, H., & Sun, Y. (2025) · Journal of Virology · doi:10.1128/jvi.00997-25 · Cited by 24
Not so cold! Improving the thermostability of mRNA vaccines
Haensler, J., Even, L., Wils, P., Bensaid, F., Dias, A., Deng, H., Karve, S., & DeRosa, F. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2596674 · Cited by 21
Metadata
- Authors
- Kim, J., Eygeris, Y., Gupta, M., & Sahay, G.
- Affiliations
- Oregon State University (US)
- Corresponding author
- Sahay, Gaurav
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 170
- Pages
- 83-112
- ISSN
- 0169-409X (ISSN-L)
- PMC
- PMC7837307
- OpenAlex
- W3119364115
- Cited by
- 514
- References
- 318
- Citations by year
- 2026: 49 · 2025: 119 · 2024: 105 · 2023: 90 · 2022: 98 · 2021: 53
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Advanced Drug Delivery Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Eye Institute
- Cystic Fibrosis Foundation
- National Heart and Lung Institute
- National Heart, Lung, and Blood Institute (1R21EY031066, 5R01HL146736, SAHAY19XX0)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- mRNA vaccines, self-assembly, mRNA delivery, lipid nanoparticles, COVID-19 vaccines, route of administration, immune activation, gene therapy, vaccine design
- MeSH terms
- COVID-19 Vaccines, mRNA Vaccines, Animals, Humans, RNA, Messenger, Vaccines, Synthetic, Drug Design, Gene Transfer Techniques, Nanotechnology, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
